Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4603257 | 0.74 | MRGPRX4 (0.40) | MRGPRX4SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL6959477 | 0.68 | MRGPRX4 (0.66) | MRGPRX4SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL30696120 | 0.68 | MRGPRX4 (0.66) | MRGPRX4SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL8135590 | 0.67 | TSPO (0.43) | MRGPRX4SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL8132061 | 0.66 | MRGPRX4 (0.40) | MRGPRX4SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL4421114 | 0.65 | RAB9A (0.58) | MRGPRX4SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL16569114 | 0.65 | MRGPRX4 (0.51) | MRGPRX4SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL27158539 | 0.65 | KMT2A (0.55) | MRGPRX4SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL6041334 | 0.65 | MRGPRX4 (0.47) | MRGPRX4SMN1; SMN2MAPTNPC1RAB9A | |
| SCHEMBL4431406 | 0.65 | MRGPRX4 (0.50) | MRGPRX4SMN1; SMN2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461117-B2 | Chemical linkers and cleavable substrates and conjugates thereof | MEDAREX, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-1940789-B1 | METHODS AND COMPOUNDS FOR PREPARING CC-1065 ANALOGS | MEDAREX INC (US) | 2011-11-23 | — | — | EP | disclosed |
| US-7847105-B2 | Methods and compounds for preparing CC-1065 analogs | MEDAREX, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100145036-A1 | CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF | MEDAREX, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20080281102-A1 | Methods and Compounds For Preparing Cc-1065 Analogs | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080281102-A1 | Methods and Compounds For Preparing Cc-1065 Analogs | CCNI, CBR3, CNR1 | MRGPRX4 981/4885SMN1; SMN2 1910/4885MAPT 4654/4885 |
| US-20100145036-A1 | CHEMICAL LINKERS AND CLEAVABLE SUBSTRATES AND CONJUGATES THEREOF | XIAP, ADAM8, CLSPN | MRGPRX4 2737/4885SMN1; SMN2 2901/4885MAPT 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.